{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:27Z","timestamp":1790806827059,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We investigated the incidence and clinical characteristics of eyes showing retinal detachment (RD) after anti-vascular endothelial growth factor (VEGF) for retinopathy of prematurity (ROP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective chart review of 76 consecutive eyes of 45 patients (18 girls and 27 boys) with stage 3 ROP who received anti-VEGF therapy between January 2012 and August 2020 with a minimum follow-up of 6 months was conducted. Eyes were divided into two groups: the vitrectomy (V) group that required vitrectomy for RD after anti-VEGF therapy and the non-vitrectomy (non-V) group that did not require vitrectomy. Data were collected from patient charts, including sex, postmenstrual age (PMA) at birth, birth weight, PMA at anti-VEGF therapy, comorbidities, reactivation, examination interval, and subsequent vitrectomies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median PMA at birth was 24.7 (range, 22.1\u201329.3) weeks. Twenty-seven eyes (35.1%) exhibited ROP reactivation at 6.4 \u00b1 3.1 weeks after anti-VEGF therapy. The V group included six eyes of five patients, all of whom exhibited reactivation and developed RD 10.1 \u00b1 6.5 weeks after anti-VEGF therapy. The types of RD were conventional (classic) in two eyes and circumferential (unique to RD after anti-VEGF) in four eyes. Three eyes required repeated vitrectomy. All eyes, except one eye in the V group, achieved retinal attachment at the last examination. The non-V group included 70 eyes of 40 patients, of which 21 exhibited reactivation and were treated successfully with laser (17 eyes) or second anti-VEGF (4 eyes). The proportion of eyes with plus disease was significantly higher in the V group (50.0%) than in the non-V group (10.0%) (<jats:italic>P<\/jats:italic> = 0.035). V group included 3 of 22 eyes (13.6%) in which the interval between the last examination and the diagnosis of reactivation was &amp;lt;1 week and 3 of 5 eyes (60.0%) in which the interval was more than 1 week (<jats:italic>P<\/jats:italic> = 0.024). The two groups showed no significant differences in the other factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Approximately 8% of eyes developed RD about 10 weeks after anti-VEGF therapy for ROP. Eyes with history of plus disease should be carefully monitored at appropriate intervals after anti-VEGF therapy for ROP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.785292","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T06:20:07Z","timestamp":1649312407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Characteristics of Eyes Developing Retinal Detachment After Anti-vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity"],"prefix":"10.3389","volume":"10","author":[{"given":"Chiori","family":"Kondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiharu","family":"Iwahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Utamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kuniyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","article-title":"Advances in understanding and management of retinopathy of prematurity","volume":"62","author":"Hartnett","year":"2017","journal-title":"Surv Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina."},{"key":"B8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: Timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","article-title":"Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab","volume":"38","author":"Yonekawa","year":"2018","journal-title":"Retina."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1097\/IAE.0000000000003249","article-title":"Clinical features and outcomes of infants with retinopathy of prematurity who fail anti-VEGF therapy","volume":"41","author":"Xu","year":"2021","journal-title":"Retina."},{"key":"B17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","article-title":"Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity","volume":"130","author":"Patel","year":"2012","journal-title":"Arch Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/ICB.0b013e318285238e","article-title":"Delayed recurrent neovascularization and persistent avascular retina following intravitreal bevacizumab for retinopathy of prematurity","volume":"7","author":"Mehta","year":"2013","journal-title":"Retin Cases Brief Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5078565","DOI":"10.1155\/2017\/5078565","article-title":"Recurrence of retinopathy of prematurity in Zone II Stage 3+ after ranibizumab treatment: a retrospective study","volume":"2017","author":"Hu","year":"2017","journal-title":"J Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1001\/archopht.1992.01080140140042","article-title":"Lens-sparing vitreoretinal surgery in infants","volume":"110","author":"Maguire","year":"1992","journal-title":"Arch Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4103\/tjo.tjo_102_18","article-title":"Current concepts and techniques of vitrectomy for retinopathy of prematurity","volume":"8","author":"Kusaka","year":"2018","journal-title":"Taiwan J Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archophthalmol.2011.253","article-title":"Modified 23-gauge vitrectomy system for stage 4 retinopathy of prematurity","volume":"129","author":"Wu","year":"2011","journal-title":"Arch Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ajo.2013.10.002","article-title":"Efficacy of short-term postoperative perfluoro-n-octane tamponade for pediatric complex retinal detachment","volume":"157","author":"Imaizumi","year":"2014","journal-title":"Am J Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00417-020-04605-y","article-title":"A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series","volume":"258","author":"Mart\u00ednez-Castellanos","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/IAE.0000000000001719","article-title":"The cutting edge of retinopathy of prematurity care: Expanding the boundaries of diagnosis and treatment","volume":"37","author":"Yonekawa","year":"2017","journal-title":"Retina."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/archopht.1984.01040030908011","article-title":"An international classification of retinopathy of prematurity","volume":"102","year":"1984","journal-title":"Arch Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000223949","article-title":"Anti-angiogenic therapy in the management of retinopathy of prematurity","volume":"44","author":"Drenser","year":"2009","journal-title":"Dev Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1167\/iovs.09-4065","article-title":"Alterations in the intraocular cytokine milieu after intravitreal bevacizumab","volume":"51","author":"Forooghian","year":"2010","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/bjophthalmol-2017-310709","article-title":"A worldwide survey of retinopathy of prematurity screening","volume":"102","author":"Mora","year":"2018","journal-title":"Br J Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.survophthal.2021.03.001","article-title":"Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: a review","volume":"66","author":"Tan","year":"2021","journal-title":"Surv Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.ophtha.2008.11.005","article-title":"Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment","volume":"116","author":"Oshima","year":"2009","journal-title":"Ophthalmology."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.785292\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T06:20:09Z","timestamp":1649312409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.785292\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":33,"alternative-id":["10.3389\/fped.2022.785292"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.785292","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"article-number":"785292"}}